- Brinkley has played a leading role in investments including US Fertility, Genetics & IVF Institute and TFP Fertility Group
- He previously worked at The Riverside Company and BlackArch Partners before joining Amulet
- Amulet manages approximately $3.8 billion of assets and is investing out of its third fund
Amulet Capital Partners has promoted Sam Brinkley to partner.
Brinkley joined the firm in 2020 as a vice president and was promoted to principal in 2024, playing a leading role in numerous investments across Amulet’s portfolio, including US Fertility, Genetics & IVF Institute, and TFP Fertility Group. He has also supported the firm’s strategic initiatives across the investment lifecycle, from sourcing and evaluating opportunities to executing transactions and working with management teams on long-term priorities.
“Since joining Amulet, Sam has been an important member of our investment team and has worked closely with our partner and portfolio companies to drive key growth and operational priorities,” said Ramsey Frank, CEO of Amulet. He added that Brinkley’s partnership mindset and deep understanding of healthcare businesses reflect the firm’s approach to investing and value creation.
Before joining Amulet, Brinkley was an investment associate with The Riverside Company. Earlier in his career, he worked at BlackArch Partners, a middle-market investment bank focused on sell-side mergers and acquisitions. He holds an MBA from the University of Chicago Booth School of Business and a bachelor’s degree in economics from Williams College.
Amulet Capital Partners is a middle-market private equity investment firm based in Greenwich, Connecticut, and Walnut Creek, California, focused exclusively on the healthcare sector. The firm manages approximately $3.8 billion of regulatory assets under management as of September 4, 2026, and is investing out of its third fund.
Editor’s note: This news brief was produced with the assistance of artificial intelligence.